• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Luminopia’s Amblyopia Treatment Gains Coverage from Highmark

by Jasmine Pennic 08/09/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Luminopia, a digital health company focused on treating neuro-visual disorders, announced today that Highmark has approved coverage for its FDA-cleared therapy for children with amblyopia. 

– This decision marks a significant milestone for Luminopia, as it expands access to its innovative treatment for a condition that affects millions of children.

What is Amblyopia?

Amblyopia, commonly known as lazy eye, is a leading cause of vision loss in children. Traditional treatments, such as eye patches and atropine drops, often result in poor patient compliance and limited efficacy. Luminopia offers a unique alternative by engaging children in therapeutic video content while addressing the underlying cause of amblyopia.

Highmark Health for Treatment of Pediatric Amblyopia

Highmark’s decision to cover Luminopia’s therapy underscores the company’s commitment to providing access to innovative treatments for its members. By approving this coverage, Highmark recognizes the unmet need for effective amblyopia therapies and the potential benefits of Luminopia’s technology.

Luminopia’s therapy has demonstrated significant improvements in vision within 12 weeks of treatment, with minimal daily usage. The company’s focus on patient engagement and compliance has led to positive outcomes for children with amblyopia.

“We appreciate Highmark’s thoughtful and rigorous approach to assessing new technologies, which can serve as a model for other health plans interested in bringing innovative therapies to their members. Meeting the Highmark NTAC’s high standards for clinical evidence is a significant validation of our technology and the impact it can have on patients with amblyopia,” said Scott Xiao, co-founder and CEO of Luminopia. “We are committed to making our treatment as accessible as possible for patients in need, and this approval brings us closer to our mission of transforming the standard of care for amblyopia.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Therapeutic Virtual Reality, Virtual Reality

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

HLTH 2025 Coverage

HLTH 2025 Day 1 Summary & Insights: AMA Launches AI Governance Center, Google Cloud, Microsoft, ChatGPT for Medicine

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Northwell Health Selects to Deploy Abridge’s Ambient AI Across 28 Hospitals

Northwell Health to Deploy Abridge’s Ambient AI Across 28 Hospitals

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |